PrEP Descovy Oral denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Descovy for PrEP as "Duplicate Therapy" — and Why You Can Appeal

A duplicate-therapy denial means UnitedHealthcare's system detected another active claim or prescription that it considers therapeutically equivalent to Descovy (emtricitabine/tenofovir alafenamide) for PrEP. In practice this often happens when a prior PrEP prescription — for Truvada, a generic emtricitabine/tenofovir disoproxil fumarate product, or another HIV-prevention regimen — appears open in the claims history, even if it has been discontinued or was never actually dispensed.

### Why This Is Appealable

Descovy and the older tenofovir disoproxil fumarate-based products, while both approved for PrEP, differ in their active tenofovir prodrug. They are not identical molecules. For patients with specific clinical profiles — such as those with certain renal or bone considerations — prescribers may determine that one product is the medically appropriate choice. A system-generated duplicate flag does not reflect a clinician's individualized assessment; it is a claims-editing rule. Federal law requires that coverage decisions be based on an individual's clinical circumstances, and a blanket duplicate-therapy edit does not satisfy that standard.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or ACA §2719 (individual/marketplace plans), you are entitled to a full and fair review. The deadline is on your denial notice.
• External review: After a final internal denial, you may request Independent Review Organization (IRO) review within approximately four months under ACA §2719.
• Expedited review: If delay would seriously jeopardize your health, request expedited review — decisions are typically required within 72 hours.

### Documentation to Gather

1. Prescriber letter of medical necessity — should explain why Descovy specifically (not a different tenofovir prodrug formulation) is the medically appropriate choice for this patient, referencing the clinical basis without quoting numeric cutoffs. 2. Documentation that the alleged duplicate is not current — pharmacy records, discontinuation notes, or a letter confirming the prior regimen is no longer active. 3. FDA prescribing labels for both products — highlighting the molecular and safety-profile distinctions between tenofovir alafenamide and tenofovir disoproxil fumarate. 4. Relevant guideline organization reference — cite CDC or USPSTF PrEP guidance generically to show that individualized drug selection is clinically supported. 5. UHC's duplicate-therapy policy — request this from UHC before filing so you can address every criterion explicitly.

### Criteria-Mapping Structure

In a two-column table, list each criterion UHC uses to define "duplicate therapy" in the left column, and provide the specific chart fact or prescriber statement that refutes the duplicate finding in the right column. Attach this as the opening exhibit of your appeal.

### Next Step

Call UHC member services and confirm which specific drug or claim triggered the duplicate flag. That information — the name of the "duplicate" and its claim date — is essential to your appeal because you must prove the alleged duplicate is either inactive, clinically distinct, or both. If the internal appeal is denied, external review is available; an IRO will assess whether the duplicate designation was clinically appropriate for your specific situation.